tirzepatide average weight loss causes more than semaglutide average weekly weight loss tirzepatide

We have these things called organ clocks

If youre on Mounjaro 2.5mg, 5mg or 7.5mg youll start on Wegovy 0.5mg

The aim of this analysis was to investigate HRQoL and work productivity of patients with - or -TDT globally

Abstract Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have emerged as a transformative class of therapies initially developed for glycemic control in type 2 diabetes mellitus

[2] [3] It belongs to a novel class of agents known as triple hormone receptor agonists , meaning it simultaneously activates three distinct receptors involved in appetite regulation and energy metabolism: GLP-1 (glucagon-like peptide-1) receptor reduces appetite and slows gastric emptying GIP (glucose-dependent insulinotropic polypeptide) receptor enhances insulin secretion and, based on preclinical and early clinical evidence, may contribute to improved fat metabolism Glucagon receptor preclinical and early clinical data suggest activation of this receptor may increase energy expenditure and promote fat breakdown (lipolysis), though the precise contribution in humans is still being characterised This triple-action mechanism distinguishes retatrutide from existing approved therapies such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GIP/GLP-1 receptor agonist)

Common contraindications include personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, or severe gastroparesis